Core Viewpoint - The A-share market experienced a broad adjustment, with major indices declining, indicating a potential shift in market sentiment and volatility [1][3]. Market Performance - The Shanghai Composite Index fell by 0.7% to 3873.32 points, while the Shenzhen Component Index dropped by 1.27%, and the ChiNext Index decreased by 1.41% [1]. - A total of 752 stocks rose, 4374 stocks fell, and 45 stocks remained unchanged across the two markets [3]. - The total trading volume in the two markets reached 1.86 trillion yuan, an increase of approximately 786.06 billion yuan compared to the previous trading day [3]. - There was a net outflow of 857.75 billion yuan in major funds [3]. Sector Performance - Wind power equipment saw a net inflow of 12.99 billion yuan, leading the sectors, followed by electric grid equipment, medical services, packaging materials, and communication services [3]. - In terms of thematic performance, space computing rose by 2.43%, and controlled nuclear fusion increased by 1.88%, with four stocks hitting the daily limit [3]. Market Outlook - Analyst Xu Xiaoming noted that the market's decline on Thursday was the largest single-day drop since the recent rebound began, but the overall drop was not significant [3]. - The market is expected to break out of its current trading range soon, which may lead to increased volatility [3]. - Xu emphasized that the current adjustments are part of an upward trend and should not be viewed as a downturn, suggesting that these adjustments could facilitate a more stable and balanced market in the future [4].

Core Points - The company has received approval from the National Medical Products Administration for the listing application of the chemical raw material drug Dolutegravir Sodium [1][3] - Dolutegravir Sodium is part of the company's fundraising project focused on the R&D of high-end generic drugs for HIV [2][3] - The approval indicates that the raw material meets national drug review technical standards, allowing for its use in domestic formulations [3] Company Information - The production enterprise is Yangzhou Aidi Pharmaceutical Technology Co., Ltd., located at No. 6 Qiqiao Road, Yangzhou High-tech Industrial Development Zone [2] - The raw material is packaged in various specifications: 20kg, 5kg, 1kg, and 0.5kg [1] Impact on the Company - The approval of Dolutegravir Sodium is expected to enhance the supply and quality of raw materials, potentially lowering production costs [3] - If the generic version of Dolutegravir Sodium is approved for market, it will diversify the company's offerings in anti-HIV medications and complement existing products [3] - The company will continue to advance the registration and listing of the formulation following the approval of the raw material [3]